Amgen announces CTO David Reese's retirement and reshapes leadership to boost AI and biotech integration.

Amgen announced the retirement of David M. Reese, its executive vice president and Chief Technology Officer, effective June 30, 2026. Reese played a key role in advancing Amgen's drug pipeline and integrating technology and AI in research and development. To continue this focus, Amgen appointed James Bradner as EVP of Research and Development, Artificial Intelligence and Data, and Sean Bruich as the new CTO. These leadership changes aim to deepen the integration of biology and technology, enhancing Amgen's innovation and patient service capabilities.